+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Not Refrigerated, Refrigerated / Other Configurations), By Application (Blood Center, Hospital, Other), By Test Format (Tube Testing, Gel Card / Microcolumn Agglutination, Cell Washing, Mixed Card-and-Tube), By Capacity (Low Capacity, Medium Capacity, High-throughput Benchtop), and Regional Forecast, 2026-2034
The global Blood Type Special Centrifuge market was valued at USD 195.3 million in 2025 and is estimated at USD 211.9 million in 2026. The market is projected to reach USD 407.0 million by 2034, exhibiting an 8.5% CAGR during 2026–2034.
Blood type special centrifuges are compact or benchtop centrifugation systems optimized for immunohematology workflows such as ABO/Rh typing, antibody screening, compatibility testing, red-cell washing and gel-card or microcolumn agglutination procedures. Unlike large blood-component centrifuges used to process whole blood bags, these instruments are designed around small tubes, cards, gel cassettes or dedicated blood-bank test formats and prioritize standardized relative centrifugal force, short cycle time, reproducibility and operator safety.
The addressable demand base is linked to the scale of transfusion services. WHO reported 120.4 million blood donations globally in its June 2026 update and emphasized that safe blood supply depends on robust testing, component preparation and quality systems. Every transfusion service must establish patient and donor compatibility using validated immunohematology methods, making standardized centrifugation a recurring laboratory infrastructure requirement rather than a discretionary analytical step.
Current product designs increasingly combine multiple workflows in one device. Bio-Rad's ID-Centrifuge L can use both ID-Cards and tubes, automatically detects the installed centrifuge head and selects the appropriate program. Grifols maintains U.S.-listed DG SPIN manual blood-grouping system equipment, while BIOBASE and LABOAO offer dedicated gel-card or blood-bank centrifuges with programmable microprocessor control. These platforms illustrate a market moving toward protocol standardization, automated program selection and flexible rotor compatibility.
The study covers specialized centrifuges used for blood typing and immunohematology rather than high-capacity blood-bag component separation alone.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | Not Refrigerated; Refrigerated / Other Specialized Configurations |
| By Application | Hospital; Blood Center; Other |
| By Test Format | Tube Testing; Gel Card / Microcolumn Agglutination; Cell Washing; Mixed Card-and-Tube Workflows |
| By Capacity | Low Capacity; Medium Capacity; High-throughput Benchtop |
| By Rotor / Carrier | Fixed-angle Tube Rotor; Swing-out Tube Rotor; Gel-card Rotor; Multi-head / Interchangeable |
| By Automation Level | Manual Program Selection; Programmable Microprocessor; Auto-head / Auto-program Selection |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | Meditech Technologies India; Thomas Scientific; Grifols; LABOAO; HERMLE Labortechnik; BIOBASE Group; Esco Scientific; DSC; Bio-Rad Laboratories |
Blood grouping and compatibility testing depend on reproducible cell separation and agglutination interpretation. Incorrect centrifugal force or timing can alter reaction patterns, so blood banks favor dedicated instruments with locked or validated programs rather than general-purpose centrifuges.
WHO reports more than 120 million blood donations globally. Blood services must support donor typing, patient testing, antibody screening and compatibility workflows, creating a stable replacement and expansion market for specialized centrifuges.
Microcolumn agglutination methods require centrifugation under tightly controlled card-specific conditions. BIOBASE offers 12- and 24-card configurations, while Bio-Rad supports a 24 ID-Card head, demonstrating the importance of dedicated card capacity.
Specialized centrifuges are lower-cost than large automated immunohematology analyzers but still compete for laboratory capital. Smaller hospitals may retain older equipment longer when test volume is low, making serviceability and total lifecycle cost important.
Automatic head detection, preset programs, countdown timing and controlled acceleration/deceleration reduce manual setup errors. These features are especially valuable in facilities with multiple technicians or high shift turnover.
Bio-Rad's ID-Centrifuge L supports both tubes and ID-Cards through interchangeable heads. Laboratories can consolidate multiple manual workflows while maintaining protocol-specific settings, which improves space utilization and purchasing efficiency.
Current LABOAO and BIOBASE models use microprocessor controls, LCD interfaces and programmable cycles. This narrows the functionality gap between premium and value systems while increasing consistency in emerging-market blood centers.
WHO's 2026 data show persistent inequality in access to safe blood and much lower donation rates in lower-income countries. Investments in national blood services therefore create opportunities for compact, reliable and affordable blood-bank instrumentation.
FDA classifies blood-bank centrifuges for IVD use as Class I and 510(k)-exempt under product code KSO, although registration, listing and quality-system obligations still apply. This supports competition from specialized manufacturers.
Blood-bank automation is increasingly connected through laboratory information systems. While many dedicated centrifuges remain standalone, future systems can add traceability, operator login, barcode-linked program selection and electronic quality records.
Centrifuge selection depends on the immunohematology method, carrier format, required RCF and degree of workflow standardization.
| Workflow | Centrifuge Requirement | Commercial Relevance |
|---|---|---|
| Tube-based blood grouping | Controlled short-duration centrifugation of red-cell suspensions and serum/plasma reactions. | Large installed base and strong replacement demand. |
| Gel-card / microcolumn agglutination | Card-specific centrifugation at validated force and time. | High-value segment tied to modern standardized blood-bank testing. |
| Red-cell washing | Repeated centrifugation and decanting/washing of cells. | Requires specialized workflow and can favor automated cell-wash centrifuges. |
| Crossmatching / antibody screening | Reliable cell sedimentation and reaction enhancement before interpretation. | Core transfusion-service application. |
| Post-transport card handling | Low-force centrifugation may restore card conditions after transport. | Specialized use supported by configurable card heads and programs. |
Not Refrigerated centrifuges lead the market because routine gel-card, tube and compatibility workflows generally use short runs at room temperature. Refrigerated and other specialized systems serve workflows requiring tighter thermal control.
Compact non-refrigerated benchtop systems dominate routine blood grouping because they are simpler, less expensive and well suited to short tube- and card-based cycles. LABOAO's MXD-4 is a current non-refrigerated example.
Refrigerated centrifugation becomes relevant for broader blood-processing or research workflows where sample temperature must be controlled. These systems carry higher capital and maintenance cost and therefore form a smaller segment within blood typing.
Blood Centers form the largest specialized application because transfusion services process donor and patient compatibility tests at high recurring volumes.
Regional and hospital blood centers perform ABO/Rh typing, antibody screening, crossmatching and related quality-control testing daily. Standardized centrifugation is central to safe release of compatible blood products.
Hospital transfusion services require rapid blood grouping and crossmatching for surgery, trauma, obstetrics, oncology and emergency care, favoring compact centrifuges close to the blood bank.
Reference laboratories, teaching institutions, research centers and specialty immunohematology facilities create additional demand for card and tube centrifugation.
Tube Testing remains broadly used, while Gel Card / Microcolumn Agglutination represents the most important standardized growth format.
Tube testing is flexible and deeply established in manual immunohematology. Multi-head systems that can accommodate 12 or 28 tubes support standardization without forcing a complete change in laboratory method.
Gel-card systems standardize reaction interpretation and are widely used for blood grouping, antibody screening and crossmatching. Dedicated 12- or 24-card rotors create a direct equipment market.
Automated or semi-automated cell washing removes plasma proteins or unbound antibodies and supports selected antiglobulin testing. Bio-Rad's DiaCent-CW is designed for conventional tube techniques requiring washing and centrifugation.
Laboratories handling multiple methodologies value systems capable of switching between cards and tubes with validated settings, reducing bench footprint and duplicate capital.
Medium-capacity benchtop instruments account for the broadest demand because they balance throughput, space and capital cost.
Small systems serve satellite hospitals and lower-volume transfusion services where a few tubes or cards are processed per batch.
Systems supporting roughly 12–28 tubes or 12–24 cards suit most hospital blood banks and regional laboratories. Bio-Rad and BIOBASE product families illustrate this capacity range.
Larger rotors and rapid acceleration/deceleration are valuable in busy blood centers but remain below the scale of automated analyzers or whole-blood component centrifuges.
North America is the largest regional market at approximately 40% of 2025 revenue. The United States has mature hospital transfusion services, strong regulatory oversight, extensive automation and recurring replacement of specialized blood-bank equipment. AABB's July 2026 blood-supply alert also illustrates the operational importance of maintaining robust blood collection and transfusion infrastructure.
Europe has highly standardized blood services and substantial adoption of gel-card immunohematology. The region supports strong demand for premium automated and semi-automated equipment, particularly in Germany, France, Italy, Spain and the United Kingdom.
Asia-Pacific is the fastest-growing major region. China and India are expanding hospital networks and centralized blood services, while local manufacturers such as LABOAO and BIOBASE improve affordability and after-sales access. WHO's 2026 blood-safety update highlights the continuing need to strengthen blood-system capacity across lower- and middle-income countries.
Brazil and Mexico are the principal markets, with demand concentrated in national blood services, major hospitals and private laboratories. Replacement of manual equipment and wider adoption of gel-card testing support growth.
GCC countries use modern blood-bank automation in tertiary hospitals, while many African markets remain under-equipped relative to transfusion need. Public investment in safe blood programs creates a long-term opportunity for durable, lower-cost benchtop systems.
Blood-bank centrifuges are relatively simple devices, but their role in transfusion compatibility places strong emphasis on validated procedures, preventive maintenance and quality control.
| Quality / Regulatory Element | Current Position | Market Effect |
|---|---|---|
| FDA classification | Blood-bank centrifuges for in-vitro diagnostic use are Class I devices under 21 CFR 864.9275, product code KSO. | Supports a defined low-risk regulatory category. |
| 510(k) status | KSO blood-bank centrifuges are 510(k)-exempt subject to device-exemption limitations. | Reduces premarket burden while retaining registration and quality obligations. |
| Blood-service quality systems | WHO emphasizes safe blood collection, testing, processing and transfusion within nationally coordinated systems. | Makes calibration and process standardization essential. |
| Program reproducibility | Dedicated devices control RCF, time and acceleration/deceleration. | Reduces operator variability and supports auditable SOPs. |
| Lid and imbalance protection | Current programmable systems use electronic lid interlocks and imbalance or overspeed protection. | Improves laboratory safety and procurement acceptance. |
Competition is fragmented across immunohematology specialists, laboratory centrifuge companies and regional value manufacturers. Workflow compatibility and service support are as important as top speed.
Grifols maintains DG SPIN within its manual blood grouping and antibody-testing ecosystem and is listed by FDA as an active 2026 manufacturer of manual blood-grouping system components.
ID-Centrifuge L supports both ID-Cards and tubes, automatic head detection, automatic program selection and four compatible heads, while DiaCent-CW addresses automated cell washing.
Meditech supplies dedicated blood-bank centrifuges across compact and higher-capacity configurations and competes through local manufacturing, service and blood-processing specialization.
MXD-4 is a current non-refrigerated blood-bank special centrifuge with 4,000 rpm maximum speed, 2,250 g maximum RCF and 12 ? 15 mL capacity.
BIOBASE offers 12- and 24-card gel centrifuges and programmable immune-blood centrifuges, targeting hospitals, blood banks and IVD laboratories.
These suppliers compete through laboratory distribution, centrifuge engineering, regional service and specialized rotor configurations.
31 August 2026: FDA's establishment and device-listing database showed Diagnostic Grifols, S.A. registered for 2026 with DG SPIN listed within its manual blood-grouping and antibody-test system portfolio.
24 July 2026: AABB warned that the U.S. blood supply had fallen significantly below desired levels, reinforcing the operational importance of blood-center readiness and reliable transfusion-service infrastructure.
12 June 2026: WHO updated its global blood safety and availability data, reporting 120.4 million blood donations worldwide and continuing disparities between high- and lower-income health systems.
2026 current portfolio: BIOBASE continued active commercial listings for 12- and 24-card gel centrifuges and immune-blood centrifuges with programmable microprocessor control and electric lid protection.
The global Blood Type Special Centrifuge market is projected to grow from USD 211.9 million in 2026 to USD 407.0 million by 2034, at an 8.5% CAGR. Growth will be led by gel-card standardization, blood-system modernization, programmable benchtop platforms and expanding transfusion infrastructure in Asia-Pacific.
| Forecast Variable | Current Direction | Expected Effect Through 2034 |
|---|---|---|
| Global blood collection | More than 120 million donations require testing and processing infrastructure. | Sustains equipment demand. |
| Gel-card adoption | Standardized microcolumn testing continues to expand. | Raises dedicated card-centrifuge share. |
| Programmable controls | Digital timing, RCF and stored protocols are becoming standard. | Supports replacement of older manual units. |
| Emerging-market access | National blood systems are expanding and modernizing. | Creates strongest unit growth. |
| Automation integration | Blood banks increasingly value traceability and standardized workflows. | Supports higher-value systems. |
The study supports blood-bank equipment strategy, transfusion-service procurement, product development, distributor planning and competitive benchmarking.
Market sizing combines bottom-up product, supplier, utilization and pricing analysis with top-down demand validation. Quantitative inputs include instrument installations or treated-patient volumes, product and technology mix, replacement or treatment cycles, end-user structure, regional access and average selling values.
Primary research validates workflow requirements, purchasing or prescribing criteria, adoption barriers and competitive positioning. Secondary research prioritizes regulators, public-health agencies, professional bodies, peer-reviewed evidence and official manufacturer information. Forecast assumptions are cross-checked against utilization, regulatory activity, technology adoption and regional healthcare capacity.
Forecasts incorporate blood-center and hospital installations, tube-versus-gel-card workflow mix, replacement cycles, average instrument pricing, transfusion infrastructure investment and regional blood-service expansion. North America remains the largest value market, while Asia-Pacific receives the strongest unit-growth assumptions.
The market was valued at USD 195.3 million in 2025 and is estimated at USD 211.9 million in 2026. It is projected to reach USD 407.0 million by 2034, representing an 8.5% CAGR.
It is used to standardize centrifugation in blood grouping, antibody screening, crossmatching, gel-card testing, tube testing and selected red-cell washing workflows.
Blood Centers are the largest specialized application because they perform high recurring volumes of donor and patient immunohematology testing.
North America is the largest regional market at approximately 40% of value, while Asia-Pacific is the fastest-growing major region.
FDA classifies blood-bank centrifuges for in-vitro diagnostic use as Class I devices under 21 CFR 864.9275, product code KSO, and they are generally 510(k)-exempt subject to applicable limitations.
Current specialized systems commonly support about 12–28 tubes or 12–24 gel cards per head or rotor depending on model.
The report profiles Meditech Technologies India, Thomas Scientific, Grifols, LABOAO, HERMLE Labortechnik, BIOBASE, Esco Scientific, DSC and Bio-Rad Laboratories.
The public overview uses 2025 as the base year, 2026 as the estimated year and 2026–2034 as the forecast period.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
